Alexander Spira, MD, PhD
Enriched profileMedical Oncologist; Co-Director, VCS Research Institute; Director, Thoracic and Phase I Program, Virginia Cancer Specialists; Chief Scientific Officer, NEXT Oncology; Clinical Assistant Professor of Oncology, Johns Hopkins University School of Medicine · Virginia Cancer Specialists
Alexander Spira is Medical Oncologist; Co-Director, VCS Research Institute; Director, Thoracic and Phase I Program, Virginia Cancer Specialists; Chief Scientific Officer, NEXT Oncology; Clinical Assistant Professor of Oncology, Johns Hopkins University School of Medicine at Virginia Cancer Specialists. OpenAlex indexes 956 publications with 29,600 citations (h-index 68); ClinicalTrials.gov lists 44 registered studies with this person as an investigator.
Data verified 25 Aug 2026
Overview
Updated 27 Aug 2026
Alexander I. Spira, M.D., is Medical Oncologist at Virginia Cancer Specialists (US Oncology Network), Fairfax, VA, clinical affiliations with Inova Fairfax Hospital and Inova Fair Oaks Hospital. The public record shows 956 publications with 29,600 citations (h-index 68), centered on Lung Cancer Treatments and Mutations, Cancer Immunotherapy and Biomarkers, Lung Cancer Research Studies. It also documents an investigator role on 44 registered clinical trials, industry payments reported by 64 companies.
- Most recent indexed publication: 2026 · Molecular cancer therapeutics
- Top research focus: Lung Cancer Treatments and Mutations
- 44 registered trials on ClinicalTrials.gov
- Open Payments reporting from 64 companies
Generated from the cited public record · current as of 27 Aug 2026. Every fact links its source below.
Indications focus
from trials led + research topicsResearch focus
OpenAlex concept fingerprintDrugs & molecules
across trials, industry payments and publicationsWorks with
trial sponsors and companies reporting paymentsScholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID; 34 in PubMed.
Total citations across indexed works.
Hirsch index (OpenAlex). i10-index 269.
Clinical & industry
trials, payments and federal fundingFederally funded research awards.
Contact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
Updated 27 Aug 2026
Listed as an investigator on 44 registered studies on ClinicalTrials.gov. The most recent:
- A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Pancreatic Cancer
Sponsor: Verastem, Inc.
- Phase 1/2 Study of BHB810 in Advanced Gastric and GEJ Adenocarcinoma
Sponsor: BigHat Biosciences, Inc.
Industry payments
Updated 27 Aug 2026
64 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:
- Janssen Biotech, Inc.Program year20257 payments$20,608openpaymentsdata.cms.gov ↗
- Merck Healthcare KGaAProgram year20255 payments$15,702openpaymentsdata.cms.gov ↗
- Boehringer Ingelheim Pharmaceuticals, Inc.Program year202514 payments$13,423openpaymentsdata.cms.gov ↗
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Blood & clotting
46.5%Iron, parenteral preparations34.7%Ferric carboxymaltose100%Part B, office-administered≥22 patientsErythropoiesis-stimulating Agent11.7%Darbepoetin alfa100%Part B, office-administered≥16 patientsCancer & immunology
35.2%CD38-directed Cytolytic Antibody24.9%Daratumumab100%Part B, office-administered≥38 patientsMicrotubule Inhibitor6.1%Paclitaxel100%Part B, office-administered≥12 patientsMusculoskeletal
7.7%RANK Ligand Inhibitor7.4%Denosumab100%Part B, office-administered≥25 patientsBisphosphonate0.3%Zoledronic acid100%Part B, office-administered≥33 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
We didn't find any NIH-funded research awards for this person in NIH RePORTER. Why? →
Publications
Updated 27 Aug 2026
Their five most recent publications, matched to their ORCID record and linked to PubMed.
- BLU-451, a CNS-Active, Potent, and Selective Small-Molecule Inhibitor Against Uncommon EGFR Mutations.
Molecular cancer therapeutics
Article2026 - BET inhibitor OPN-2853 in advanced solid tumors and lymphoma: results from the phase 1b PLX124-01 trial.
Cancer chemotherapy and pharmacology
Clinical Trial2026 - Phase 1 Study of INBRX-105, a TNFRSF9 (4-1BB) and PD-L1 Bispecific Antibody, in Patients with Select Solid Tumors.
Cancer research communications
Clinical Trial2026 - Amivantamab Plus Lazertinib in Atypical EGFR-Mutated Advanced Non-Small Cell Lung Cancer: Results From CHRYSALIS-2.
Journal of clinical oncology
Article2026
Most-cited works
by citation count (OpenAlex)- 01
- 02Sotorasib for Lung Cancers with <i>KRAS</i> p.G12C Mutation1,778 citations2021
- 03
- 05Multidisciplinary Management of Lung Cancer925 citations2004
Network
Updated 27 Aug 2026
The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.
Online presence
Updated 27 Aug 2026
This person's own public accounts first, then places where others mention them. Two different things, listed separately.
Owned accounts
public accounts run by this person- Doximity
doximity.com/pub/alexander-spira-md
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doximity.com ↗ - LinkedIn
linkedin.com/in/alex-spira
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →linkedin.com ↗ - ResearchGate
researchgate.net/profile/Alexander-Spira
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →researchgate.net ↗
Mentions by others
where others cite or feature them- Other
nextoncology.com/next-oncology-names-dr-alex-spira-chief-scientific-officer
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →nextoncology.com ↗ - Other
virginiacancerspecialists.com/physician/alex-spira-m-d-phd-f-a-c-p
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →virginiacancerspecialists.com ↗ - Other
inova.org/doctors/alexander-i-spira-md
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →inova.org ↗
We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.
Background & recognition
Updated 27 Aug 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Education
degrees and training on record- MD
New York University School of Medicine (Grossman School of Medicine)
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →inova.org ↗ - PhD
New York University (Graduate School of Arts and Science), institution name appears inconsistently across sources as "New York University" vs "New York School of Arts and Sciences"
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →virginiacancerspecialists.com ↗ - Board Certified
Medical Oncology (ABMS Member Board)
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →inova.org ↗ - Residency
Internal Medicine, Hospital of the University of Pennsylvania
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →virginiacancerspecialists.com ↗ - Fellowship
Hematology/Oncology (Medical Oncology), Johns Hopkins Hospital
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →inova.org ↗
Editorial & leadership roles
journal and society appointments- Fellow
American College of Physicians (FACP)
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →virginiacancerspecialists.com ↗ - Fellow
American Society of Clinical Oncology (FASCO)
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →ajmc.com ↗ - Co-Chair
US Oncology Thoracic Oncology Committee
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →virginiacancerspecialists.com ↗
Awards & honors
honors on the public record- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →virginiacancerspecialists.com ↗
- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →virginiacancerspecialists.com ↗
- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →nextoncology.com ↗
Secondary affiliations
appointments beyond the home institution- Clinical Assistant Professor of Oncology
Johns Hopkins University School of Medicine
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →virginiacancerspecialists.com ↗ - Chief Scientific Officer
NEXT Oncology (also leads NEXT Oncology – Virginia)
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →nextoncology.com ↗
Media & interviews
press, podcasts and appearances- OncLive contributing author/interviewee
frequent "OncLive On Air" commentary, e.g. "FDA Approval Insights: Subcutaneous Amivantamab for EGFR-Mutated NSCLC"
2025verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →onclive.com ↗ - verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →vjoncology.com ↗
- NBC4 "For Your Sunday Viewpoint" interview with Pat Lawson Muse on lung cancer treatment highlights
tied to LUNGevity DC Walk
2016verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →virginiacancerspecialists.com ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.